Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 18Melanoma 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Breast Neoplasms 8Head and Neck Neoplasms 6Esophageal Squamous Cell Carcinoma 6Rectal Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Neoplasms 4Carcinoma, Renal Cell 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Radiation Pneumonitis 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oropharyngeal Neoplasms 2

Interventions

Sorafenib 4Blood Specimen Collection 4lenvatinib 3sintilimab 2halofantrine 2camrelizumab 2Liver Transplantation 2Antibodies 2trametinib 1toripalimab 1titanium silicide 1tislelizumab 1pembrolizumab 1ledipasvir, sofosbuvir drug combination 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1bavituximab 1avatrombopag 1aumolertinib 1atezolizumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Sofosbuvir 1Shadowing Technique, Histology 1Ropivacaine 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver Diseases × Immunotherapy × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡